GLOBAL DIABETES DRUGS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL DIABETES DRUGS MARKET FORECAST 2019-2027

GLOBAL DIABETES DRUGS MARKET FORECAST 2019-2027

The significant increase in the Diabetes Drugs market can be attributed to the market growth of both Type 1 and Type 2 Diabetes Drugs market and the increasing rate of occurrence of these diseases. The global diabetes drugs market was valued at $34295 million in 2018 & is estimated to generate net revenue of approximately $60434.87 million by 2027, growing at a CAGR of 6.50% .

GLOBAL DIABETES DRUGS MARKET FORECAST 2019-2027

Global Diabetes Drugs Market is segmented by Diabetes Type( Type 1, Type 2) by Product Class( Insulin (Fast Acting Insulin, Intermediate Acting Insulin, Long-acting Insulin) Non-Insulin (DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors)) & by Geography

Request free sample 

The significant increase in the Diabetes Drugs market can be attributed to the market growth of both Type 1 and Type 2 Diabetes Drugs market and the increasing rate of occurrence of these diseases. The global diabetes drugs market was valued at $34295 million in 2018 & is estimated to generate net revenue of approximately $60434.87 million by 2027, growing at a CAGR of 6.50% . The base year considered for the study is 2018 and the forecasted period is 2019-2027.

The Diabetes Drugs market is primarily driven by the following factors:

  • Increase in the prevalence of diabetes
  • Advances in insulin delivery technology
  • Growing elderly population

Global Diabetes Drugs Market

To know more about this report, request a free sample copy

The important driver for the growth in this market is the increase in the prevalence of diabetes which is a result of increasing obesity among people caused by unhealthy diets and sedentary lifestyles. Also, obese individuals are five times more likely to be diagnosed with diabetes than individuals with normal weight. According to research, approximately 13% of the world population is obese, and this increases the risk of developing diabetes, further propelling the market growth. Also, the growing elderly population is influencing the market growth in a big way as the life expectancy rate is rising and the birth rate is declining at the same time. With the increase in the ageing population, the expectancy rate of diabetes is expected to increase with time.

The important challenges faced by both the markets commonly is poor storage conditions and distribution policies for insulin. Insulin is required to be stored at specific conditions to maintain its efficacy, which further increases its cost, especially in low and middle-income countries. Also, there are inadequate distribution policies and a lack of centralized supply chains for insulin which influences the price variations among the countries.

The Diabetes Drugs market segments includes diabetes type and product class.

Diabetes Type is segmented into:

  • Type 1
  • Type 2

Product Class is segmented into:

  • Insulin
    • Fast acting insulin
    • Intermediate-acting insulin
    • Long-acting insulin
  • Non-insulin
    • DPP-4 inhibitor
    • GLP-1 receptors agonists
    • SGLT-2 inhibitors
    • Other non-insulin drugs

This report covers the present market conditions and the growth prospects of the global diabetes drugs market for 2019-2027 and considered the revenue generated through the sales of diabetes drugs for diabetes type as well as product class to calculate the market size by considering 2017 as the base year.

Geographically, the diabetes drugs market has been segmented on the basis of four major regions, which include:

The Diabetes Drugs market in North America is expected to hold the largest share by 2027 due to the maximum prevalence of diabetic population. The US consumes more than 77% of the total demand for diabetes drugs in the region. The country is followed by Canada. North America has many diabetes drugs manufacturers that offer products for use by both the types (type 1 and type 2) of diabetic patients.

The diabetes drugs market is segmented based on its product class; which are sub-divided into insulin, non-insulin and other emerging products. Insulin is further sub-divided into Fast Acting Insulin, Intermediate Acting Insulin and Long Acting Insulin, while Non-Insulin is further divided into DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors and others. Fast-acting insulin gets rapidly absorbed into the bloodstream and is further used to control and correct high blood glucose levels during meals. Intermediate-acting insulin is absorbed slowly as compared to fast-acting insulin and thus controls blood glucose levels overnight, while fasting, and between meals. Long-acting insulin is absorbed slowly into the bloodstream which lasts a day.

The major market players in the global diabetes drugs market are:

  • Novo Nordisk A/S
  • Sanofi
  • Merck
  • Eli Lilly And Company
  • AstraZeneca

Company Profiles covers analysis of important players.

Novo Nordisk is a global healthcare company engaged in providing diabetes and obesity care products. The company also has a leadership position in haemophilia, growth hormone therapy and hormone replacement therapy. Novo Nordisk operates in Europe, North America, China, Japan, Korea and other regions of the world. It is headquartered in Bagsvaerd, Denmark. Sanofi SA (Sanofi or ‘the group’) is a France-based international pharmaceutical group engaged in research, development, manufacture and marketing of healthcare products. The group classifies its business into two operating segments: Pharmaceuticals, and Human Vaccines. It offers a range of products related to rare diseases, multiple sclerosis, oncology, diabetes, and cardiovascular diseases.

Key Findings of the Global Diabetes Drug market:

  • North America holds the largest market share
  • Rising prevalence of type 2 diabetes
  • Insulin market is anticipated to generate the highest revenue
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • NORTH AMERICA HOLDS THE LARGEST MARKET SHARE
      • RISING PREVALENCE OF TYPE 2 DIABETES
      • INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • INCREASE IN PREVALENCE OF DIABETES
      • ADVANCES IN INSULIN TECHNOLOGY
      • GROWING ELDERLY POPULATION
    • MARKET RESTRAINTS
      • STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
      • LACK OF AWARENESS AMONG PEOPLE
      • COST SENSITIVITY ISSUES
    • MARKET OPPORTUNITIES
      • DEVELOPMENT OF NEW FORMULATIONS
      • INCREASING RESEARCH AND DEVELOPMENT
    • MARKET CHALLENGES
      • FIERCE MARKET COMPETITION
      • RISING CONCERNS IN SCIENTIFIC COMMUNITY
      • GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
      • POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN
  1. MARKET SEGMENTATION
    • MARKET BY DIABETES TYPE 2019-2027
      • TYPE 1
      • TYPE 2
    • MARKET BY PRODUCT CLASS 2019-2027
      • INSULIN
        • FAST ACTING INSULIN
        • INTERMEDIATE ACTING INSULIN
        • LONG-ACTING INSULIN
      • NON-INSULIN
        • DPP-4 INHIBITOR
        • GLP-1 RECEPTORS AGONISTS
        • SGLT-2 INHIBITORS
        • OTHER NON-INSULIN DRUGS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • ETYMOLOGY OF DIABETES DRUGS MARKET
    • LEGAL, POLICY AND REGULATORY ISSUES
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • RUSSIA
      • ITALY
      • DENMARK
      • NORWAY
      • AUSTRIA
      • SWITZERLAND
      • SWEDEN
      • NETHERLANDS
      • REST OF EUROPE
    • ASIA-PACIFIC (APAC)
      • CHINA
      • INDIA
      • AUSTRALIA
      • JAPAN
      • SOUTH KOREA
      • INDONESIA
      • MALAYSIA
      • PHILIPPINES
      • THAILAND
      • VIET NAM
      • REST OF ASIA-PACIFIC (ROAPAC)
    • REST OF THE WORLD (ROW)
      • LATIN AMERICA
        • BRAZIL
        • MEXICO
        • REST OF LATIN AMERICA
      • MIDDLE-EAST AND AFRICA
  1. COMPANY PROFILES
    • ELI LILLY AND COMPANY
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ASTRAZENECA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BRAUN MELSUNGEN AG
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC ANALYSIS
    • NOVO NORDISK A/S
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SANOFI
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • DIAVACS INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • XOMA CORP.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ALBIREO PHARMA INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • MACROGENICS, INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • ASTELLAS PHARMA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GLAXOSMITHKLINE
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • MERCK
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • XERIS PHARMACEUTICALS
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES

 

LIST OF TABLES

TABLE  1      GLOBAL DIABETES DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  2      GLOBAL DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)

TABLE  3      GLOBAL DIABETES DRUGS MARKET IN TYPE 1 DIABETES BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  4      GLOBAL DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 BY GEOGRAPHY ($ MILLIONS)

TABLE  5      GLOBAL DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)

TABLE  6      GLOBAL DIABETES DRUGS MARKET IN INSULIN TYPE BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  7      GLOBAL DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)

TABLE  8      GLOBAL INSULIN MARKET IN FAST ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  9      GLOBAL INSULIN MARKET IN INTERMEDIATE ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  10    GLOBAL INSULIN MARKET IN LONG ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  11    GLOBAL DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  12    GLOBAL DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)

TABLE  13    GLOBAL NON INSULIN DRUGS MARKET IN  DPP-4 INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  14    GLOBAL NON INSULIN DRUGS MARKET IN  GLP-1 RECEPTORS AGONISTS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  15    GLOBAL NON INSULIN DRUGS MARKET IN  SGLT-2 INHIBITORS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  16    GLOBAL NON INSULIN DRUGS MARKET IN  OTHER NON INSULIN DRUGS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  17    GLOBAL DIABETES DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  18    NORTH AMERICA DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  19    EUROPE DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  20    ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  21    REST OF THE WORLD DIABETES DRUGS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  22    LATIN AMERICA DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

FIGURE  1    GLOBAL DIABETES DRUGS MARKET 2019-2027 ($ BILLION)

FIGURE  2    GLOBAL DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)

FIGURE  3    AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY CONTINENT AND GENDER (IN YEARS)

FIGURE  4    PORTER’S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET

FIGURE  5    THE UNITED STATES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  6    CANADA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  7    THE UNITED KINGDOM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  8    FRANCE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  9    GERMANY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  10  RUSSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  11  ITALY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  12  DENMARK DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  13  NORWAY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  14  AUSTRIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  15  SWITZERLAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  16  SWEDEN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  17  NETHERLANDS DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  18  REST OF EUROPE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  19  CHINA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  20  INDIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  21  AUSTRALIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  22  JAPAN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  23  SOUTH KOREA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  24  INDONESIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  25  MALAYSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  26  PHILIPPINES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  27  THAILAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  28  VIETNAM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  29  REST OF ASIA-PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  30  BRAZIL DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  31  MEXICO DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  32  REST OF LATIN AMERICA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  33  MIDDLE-EAST AND AFRICA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

  1. MARKET SEGMENTATION
    • MARKET BY DIABETES TYPE 2019-2027
      • TYPE 1
      • TYPE 2
    • MARKET BY PRODUCT CLASS 2019-2027
      • INSULIN
        • FAST ACTING INSULIN
        • INTERMEDIATE ACTING INSULIN
        • LONG-ACTING INSULIN
      • NON-INSULIN
        • DPP-4 INHIBITOR
        • GLP-1 RECEPTORS AGONISTS
        • SGLT-2 INHIBITORS
  1. OTHER NON-INSULIN DRUGS GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • RUSSIA
      • ITALY
      • DENMARK
      • NORWAY
      • AUSTRIA
      • SWITZERLAND
      • SWEDEN
      • NETHERLANDS
      • REST OF EUROPE
    • ASIA-PACIFIC (APAC)
      • CHINA
      • INDIA
      • AUSTRALIA
      • JAPAN
      • SOUTH KOREA
      • INDONESIA
      • MALAYSIA
      • PHILIPPINES
      • THAILAND
      • VIET NAM
      • REST OF ASIA-PACIFIC (ROAPAC)
    • REST OF THE WORLD (ROW)
      • LATIN AMERICA
        • BRAZIL
        • MEXICO
        • REST OF LATIN AMERICA
      • MIDDLE-EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now